HC Wainwright Issues Negative Estimate for Evommune Earnings

Evommune, Inc. (NYSE:EVMN) – Analysts at HC Wainwright dropped their Q1 2026 earnings estimates for Evommune in a report released on Wednesday, March 18th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($0.83) per share for the quarter, down from their previous forecast of ($0.36). HC Wainwright currently has a “Buy” rating and a $50.00 price target on the stock. HC Wainwright also issued estimates for Evommune’s Q2 2026 earnings at ($0.71) EPS, Q3 2026 earnings at ($0.71) EPS, Q4 2026 earnings at ($0.75) EPS and FY2026 earnings at ($3.00) EPS.

Other research analysts have also issued reports about the stock. Clear Str upgraded shares of Evommune to a “strong-buy” rating in a research note on Tuesday. The Goldman Sachs Group upgraded Evommune to a “buy” rating in a research note on Wednesday, January 7th. Raymond James Financial began coverage on Evommune in a research note on Wednesday, January 7th. They set a “strong-buy” rating and a $40.00 price objective for the company. Oppenheimer initiated coverage on Evommune in a report on Thursday, January 22nd. They issued an “outperform” rating and a $42.00 target price on the stock. Finally, Zacks Research upgraded Evommune to a “hold” rating in a report on Tuesday, December 2nd. Three research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $47.17.

Evommune Stock Performance

Shares of EVMN stock opened at $23.32 on Friday. Evommune has a twelve month low of $13.89 and a twelve month high of $33.20. The stock has a market capitalization of $839.76 million and a PE ratio of -2.89. The business has a fifty day moving average price of $23.26.

Evommune (NYSE:EVMN) last issued its quarterly earnings data on Thursday, March 5th. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.61).

Hedge Funds Weigh In On Evommune

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Evommune during the fourth quarter valued at $34,000. The Manufacturers Life Insurance Company bought a new stake in Evommune during the fourth quarter valued at approximately $179,000. XTX Topco Ltd purchased a new stake in shares of Evommune in the 4th quarter worth $321,000. Oxford Asset Management LLP bought a new position in shares of Evommune in the fourth quarter worth about $335,000. Finally, State Street Corp bought a new position in Evommune in the 4th quarter worth $539,000.

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.